Buy Aurobindo Pharma for Rs 1450-1500 target in 3 weeks: Devang Visaria

In a chat with ET Now, Devang Visaria, Chief Strategist, devangvisaria.com, shares his views on the outlook of Aurobindo Pharma and Cipla.

What would you choose between large-cap pharma and mid-cap pharma?

You could possibly again look at Aurobindo Pharma. Although it is not a large-cap stock. Aurobindo Pharma is looking good from a medium term to positional perspective. With a three weeks' time horizon, we are looking for targets closer to Rs 1,450-1,500 for Aurobindo Pharma. Cipla is also doing all the right things on the charts and possibly on the upside, Rs 370-375 could be a good target for Cipla.